Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) went down by -2.32% during the previous trading session, and it is maintaining the win ahead of Wednesday’s trading session. The share price of the Biotechnology giant went up by $609.17 to trade ended Wednesday trading at $623.65. This is down from the $623.65 price recorded on Tuesday’s trading session. Thanks to this latest performance, REGN is closer to the higher price 52-week target of $734.00 and further from the lowest price target of $400.00. Its performance from the start of the year has also been positive, with REGN up by 62.24% year-to-date.
Regeneron Pharmaceuticals Inc. (REGN) started the day trading at $625 and recorded an intraday high of $625. It also recorded an intraday low of $601.02 during Wednesday’s trading session. Regeneron Pharmaceuticals Inc. is a very active stock that recorded a trading volume that is less than -43.32% of the average daily trading volume on Wednesday. The stock’s trading volume on Wednesday was 983821, which is less than -43.32 of the total average daily trading volume of 1.41 million.
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) 2020 Performance Impressive
The increase in REGN’s stock price on Wednesday saw its overall performance boost over the past few months. We can quantify the performance of the stock so far this year using a few metrics. The 52-week high price of REGN currently stands at $646.33, which is higher than the current trading price of the stock by 5.75%. However, REGN’s current trading price is -124.48% lower than the 52-week low price of $271.37. In terms of trading volume, Regeneron Pharmaceuticals Inc. currently experienced healthy participation during the last trading session. 983821 shares of Regeneron Pharmaceuticals Inc. were traded on the stock exchange on Wednesday, which is less than -43.32% of the 1.41 million average trading volume of the stock.
The performance of the stock has been positive over the past year. REGN’s performance over the past one year has seen it surge by 93.06%, while the stock has gone up by 62.24% in the last six months. The quarterly performance of REGN currently stands at 22.66%, and it is down by -1.37% in the last month. The only positive figure was from the weekly performance, which currently reads 0.68%. At the time of writing REGN’s report, the company has a total market cap of $69.51B, making it one of the largest publicly-traded companies in the world.Regeneron Pharmaceuticals Inc. also has over 8100 employees all over the world.
REGN Insider Activities
For Regeneron Pharmaceuticals Inc., insiders hold 69.80% of all company shares. The insider transactions over the past six months are down by -45.80%. During that period, insiders bought 1,332,807 shares in 81 transactions. In that same period, insiders sold 1,714,754 of their shares in 559 transactions. After these transactions, insiders at Regeneron Pharmaceuticals Inc. now hold 26.52M shares, which is over 68.35% of the total company stocks. Institutional investors currently hold a large chunk of the REGN shares, as they control 23.82% of the company’s total stock.
REGN Fundamental Analysis
For Regeneron Pharmaceuticals Inc., the stock’s diluted earnings per share (EPS) stands at 19.90. In the coming year, analysts expect the EPS to be 31.87. The EPS growth will up over the next five years to 8.44% after surging by 44.00% in the previous five years. In terms of revenue, Regeneron Pharmaceuticals Inc.’s quarterly sales (YOY) is growing at 6.14, which is lower than the average annual revenue of 44.00% over the past half a decade.
The Return on Investment (ROI) on Regeneron Pharmaceuticals Inc.’s stock currently stands at 16.10%, and it has a net profit margin of 28.60%. The operating margin of the company is 30.50%, and its gross margin is 89.70%.
REGN Analysts Prediction
In May 26, 2020, several analysts reiterated their positions on the Regeneron Pharmaceuticals Inc. stock and predicted its performance to their investors. The analysts at Wells Fargo believe REGN is still a Overweight and set the price target between $559 and $734. The Citigroup has a Neutral rating for Regeneron Pharmaceuticals Inc., predicting the stock price to stay between $540 and $575.
At the moment, Regeneron Pharmaceuticals Inc.’s Total Debt to Equity ratio stands at 0.06, and they have a long-term Debt to Equity ratio of 0.06.
REGN Technical Analysis
The Simple Moving Average (SMA) is one of the most powerful technical indicators. The 20-day Simple Moving Average of REGN currently stands at 0.20%, while the SMA50 is 4.99%. The biggest one is the SMA200, which is currently reading 41.65% ahead of Wednesday’s trading session. The Relative Strength Index of this stock is 52.93, while its price to earnings ratio (P/E) is 30.61.
